WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H510350
CAS#: 1443460-91-0
Description: GSK2838232 is a novel human immune virus (HIV) maturation inhibitor being developed for the treatment of chronic HIV infection. GGSK2838232 is derived from the triterpene betulin natural product that has demonstrated an excellent virological profile against a panel of viruses and retains activity to viruses with key resistance mutations.
Hodoodo Cat#: H510350
Name: GSK2838232
CAS#: 1443460-91-0
Chemical Formula: C48H73ClN2O6
Exact Mass: 808.52
Molecular Weight: 809.570
Elemental Analysis: C, 71.21; H, 9.09; Cl, 4.38; N, 3.46; O, 11.86
Related CAS #: 1443460-91-0 1443461-21-9 (GSK2838232-isomer)
Synonym: GSK2838232; GSK-2838232; GSK 2838232.
IUPAC/Chemical Name: 4-(((3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-((R)-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
InChi Key: MEOWKUXNVNJAMY-PZFKGGKESA-N
InChi Code: InChI=1S/C48H73ClN2O6/c1-30(2)40-34(52)26-48(37(53)29-51(25-24-50(10)11)28-31-12-14-32(49)15-13-31)23-22-46(8)33(41(40)48)16-17-36-45(7)20-19-38(57-39(54)27-43(3,4)42(55)56)44(5,6)35(45)18-21-47(36,46)9/h12-15,30,33,35-38,53H,16-29H2,1-11H3,(H,55,56)/t33-,35+,36-,37+,38+,45+,46-,47-,48+/m1/s1
SMILES Code: CC(C)([C@](CC[C@@]([C@](CC[C@@]1([C@@H](O)CN(CC2=CC=C(Cl)C=C2)CCN(C)C)C3)4C)5C)6[H])[C@@H](OC(CC(C)(C(O)=O)C)=O)CC[C@]6(C)[C@@]5([H])CC[C@]4([H])C1=C(C(C)C)C3=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | GSK2838232 inhibits HIV reverse transcriptase activity across a broad panel of HIV-1 isolates. |
In vitro activity: | TBD |
In vivo activity: | TBD |
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 25.0 | 30.88 |
The following data is based on the product molecular weight 809.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | TBD |
In vitro protocol: | TBD |
In vivo protocol: | TBD |
1: Shamshina JL, Rogers RD. Are Myths and Preconceptions Preventing us from Applying Ionic Liquid Forms of Antiviral Medicines to the Current Health Crisis? Int J Mol Sci. 2020 Aug 20;21(17):6002. doi: 10.3390/ijms21176002. PMID: 32825444; PMCID: PMC7503643.
2: Johnson M, Jewell RC, Gan J, Dumont E, Burns O, Johns BA. A Phase 1 Study to Assess the Relative Bioavailability, Food Effect, and Safety of a Tablet Formulation of GSK2838232, a Novel HIV Maturation Inhibitor in Healthy Participants After Single and Repeated Doses. Clin Pharmacol Drug Dev. 2020 Nov;9(8):972-977. doi: 10.1002/cpdd.820. Epub 2020 Jun 18. PMID: 32558338.
3: DeJesus E, Harward S, Jewell RC, Johnson M, Dumont E, Wilches V, Halliday F, Talarico CL, Jeffrey J, Gan J, Xu J, Felizarta F, Scribner A, Ramgopal M, Benson P, Johns BA. A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection. Clin Infect Dis. 2020 Aug 22;71(5):1255-1262. doi: 10.1093/cid/ciz938. PMID: 31769793.
4: Johnson M, Jewell RC, Peppercorn A, Gould E, Xu J, Lou Y, Davies M, Baldwin S, Tenorio AR, Burke M, Jeffrey J, Johns BA. The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects. Pharmacol Res Perspect. 2018 Jun 5;6(4):e00408. doi: 10.1002/prp2.408. PMID: 29930812; PMCID: PMC5989765.